All In Biotech

Drug Trial Radar · NCT07152041

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

A Phase 3, Multicenter Trial for Pediatric Philadelphia Chromosome-positive B-Acute Lymphoblastic Leukemia -2025 Project

Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Mar 28, 2025

Primary completion

Dec 2029

Study completion Jun 2030

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed pediatric/adolescent patients with Ph+ ALL. The CCCG-Ph+ B-ALL-2025 protocol will be modified as following compared to the CCCG-ALL-2020 protocol

Conditions

  • Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
  • Childhood Leukemia, Acute Lymphoblastic

Interventions

  • olverembatinibDrug

    All Ph+-ALL patients will uniformly use the 3rd generation of TKI olverembatinib (OVB) instead of dasatinib throughout the regimen. OVB is combined with Vincristine and Prednisone (VP) during the first 2 weeks and with blinatumomab during the last 4 weeks of remission induction in this protocol. Patients will receive blinatumomab for 28 days as induction instead of CAT to improve induction response and avoid toxicity. All patients will receive two cycles of HDMTX+Blina-14 and 4 times of triple intrathecal therapy (TIT) throughout the consolidation 1 phase. To decrease the toxicities of high-dose AraC, the dosage will be reduced to 1 g/m2 in the consolidation 2 phase in contrast to 2 g/m2 in 2020 protocol. Throughout the early Maintenance Therapy, dexamethasone and vincristine combination will be added with either venetoclax or daunorubicin alternatively for five cycles, given after MTX and 6-MP.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Day 48 end-of-induction measurable residual diseases (MRD48) after induction remission with olverembatinib and blinatumomab, compared to MRD46 of those treated with dasatinib plus chemotherapy induction (CCCG-ALL-2015 /2020) or from historical cohorts .Time frame: Up to approximately 4.5 years.

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Anhui Medical University Second Affiliated Hospita

    Hefei, Anhui, China · Not yet recruiting

  • Chongqing Medical University Affiliated Children's Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Guangzhou Women and Children's Medical Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Wuhan Children's Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Children's Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Third Xiangya Hospital of the Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Nanjing Children's Hospital Affiliated to Nanjing Medical University

    Nanjin, Jiangsu, China · Not yet recruiting

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • Jiangxi Provincial Children's Hospital

    Nanchang, Jiangxi, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Not yet recruiting

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shanghai Children's Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Shenzhen Children's Hospital

    Shenzhen, Shenzhen, China · Not yet recruiting

  • West China Second University Hospita

    Chengdu, Sichuan, China · Not yet recruiting

  • Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC

    Tianjin, Tianjin Municipality, China · Recruiting

  • Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Hong Kong Children's Hospital, The Chinese University of Hong Kong

    Hong Kong, Hong Kong · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.